Chimerix Announces Data Highlighting Clinical Efficacy And Molecular Mechanisms Of Response To ONC201 Treatment Of H3 K27M-Mutant Diffuse Midline Gliomas Published In "Cancer Discovery"
Portfolio Pulse from Happy Mohamed
Chimerix (NASDAQ:CMRX) has published data demonstrating the clinical efficacy of its first-in-class small molecule imipridone, ONC201, as a treatment for H3 K27M-mutant diffuse midline gliomas. The study showed a statistically significant increase in median overall survival (mOS) from diagnosis versus historical controls (21.7 months mOS vs. 12 months mOS). The company's CEO, Mike Andriole, stated that while these results require validation in prospectively designed studies, they provide ongoing confidence for ONC201's monotherapy treatment effect.
August 16, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chimerix's ONC201 has shown promising results in treating H3 K27M-mutant diffuse midline gliomas, potentially leading to increased investor confidence in the company.
The positive results from the study of ONC201 could lead to increased investor confidence in Chimerix, potentially leading to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100